Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents HiVentures Zrt., a Hungarian Venture Capital Company, in Private Placement of Series A Preferred Stock of ActiveGraf - January 16, 2020
- Trusts and Estates Attorney - January 13, 2020
- Sichenzia Ross Ference LLP Represents A.G.P./Alliance Global Partners as Sole Placement Agent in $3M Registered Direct Offering of Cellect Biotechnology Ltd. - January 10, 2020